Category Archives: Biotechnology

Julie Kelly, cooking instructor, food writer, blogger and a Mom who lives in the Chicago area. In 2015, she got passionate about GMOs. Kelly is a contributing writer to the Wall Street Journal, National Review, Huffington Post, The Hill and other media outlets.| March 2, 2017 HIGHLIGHTS: Hollywood is in our homes daily,often spreading misconceptions about science, and GE crops in particular Gary Hirshberg, founder of Stonyfield Organic and Just Label It, is the key celebrity organizer Gwyneth Paltrow has emerged as the face of celebrity moms who question the safety of GE foods Mark Ruffalo questions GE foods but also rejects biotechnological solutions beyond food, such as the gene-edited mosquito that could curtail the Zika virus Celebrity misinformation campaigns have filled a void created by the agricultural and food industries, which have been reticent to defend the science of biotechnology While the Internet and social media are valuable tools for disseminating information about complicated subjects like science and agriculture, it has also given rise to a modern-day monster: the expert celebrity From movie stars to television chefs, a cadre of self-promoting yet often ill-informed celebrities are influencing the public discussion about topics way beyond their expertise, particularly consequential issueslike … Continue reading →

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced publication of abstracts on neratinib for the American Association for Cancer Research (AACR) Annual Meeting 2017. The AACR Annual Meeting will be held at the Walter E. Washington Convention Center in Washington, D.C. from April 1 to April 5. Full abstracts of the following presentations are available online at http://www.aacr.org: Apr. 4, 2017, 1:00 - 5:00 p.m. EDT Abstract 4818 (Poster): Neratinib/fulvestrant but not fulvestrant alone maintain complete tumor responses after treatment with trastuzumab + paclitaxel of mice bearing ER+/HER2+ xenografts. L.J. Schwarz et al, Vanderbilt University Medical Center. April 4, 2017, 1:00 - 5:00 p.m. EDT Abstract 4157 (Poster): Co-blockade of mTORC1, ERBB and estrogen receptor signaling pathways in endocrine resistant breast cancer: combating tumour plasticity. R. Ribas et al, Institute of Cancer Research. April 4, 2017, 1:00 - 5:00 p.m. EDT Abstract 4038 (Poster): Exploring optimal targeted combination therapies with neratinib for HER2+ breast cancer. M. Zhao et al, MD Anderson Cancer Center. April 5, 2017, 8:00 - 12:00 p.m. EDT Abstract 5167 (Poster): Stem-like colorectal cancer cell lines show response to the ERK1/2 inhibitor, SCH772984, alone and in combination with neratinib while the combination of MEK-162 … Continue reading →

Posted Feb. 28, 2017 at 3:39 p.m. Published: 2017-02-28 15:39:55 Updated: 2017-02-28 15:39:55 By JIM SHAMP, NCBiotech Writer Raleigh, N.C. The North Carolina Biotechnology Center has announced that Pfizer has committed to providing funding in the amount of $4 million which will enable the Center to establish and administer a multi-year academic fellowship program to help advance North Carolinas fast-growing expertise in gene therapy. The new program, to be managed by NCBiotech, will support distinguished postdoctoral fellowships in North Carolina university research laboratories providing advanced scientific training in gene therapy-related research. Absent or faulty proteins linked to genetic mutations cause numerous devastating diseases, making gene therapy an increasingly important treatment strategy. Pfizers portfolio in North Carolina has grown in recent years. The company already operates a pharmaceutical manufacturing facility in the Lee County community of Sanford, and in August 2016, it acquired leading-edge gene therapy company Bamboo Therapeutics, Inc. in Chapel Hill. With that acquisition, Pfizer gained the expertise of Bamboos world-renowned co-founder, R. Jude Samulski, Ph.D., director of the Gene Therapy Centerat the University of North Carolina at Chapel Hill. The deal also included an 11,000-square-foot facility for the highly specialized manufacturing of recombinant adeno-associated viral vectors. Pfizer is … Continue reading →

Wall Street Journal (subscription) Nasdaq Slips as Biotechnology Shares Decline Wall Street Journal (subscription) Declines in biotechnology shares dragged down the Nasdaq Composite, pressuring an index that has soared so far this year. The Nasdaq fell 0.4% Thursday but is up more than 8% in 2017, outperforming both the Dow Jones Industrial Average and the S&P ... and more » Continued here: Nasdaq Slips as Biotechnology Shares Decline - Wall Street Journal (subscription) … Continue reading →

WASHINGTON, Feb. 23, 2017 Iowa Gov. Terry Branstad, President Trumps choice to be the next U.S. ambassador to China, said today that if confirmed he will make it a priority to get China to lift its ban on U.S. beef and reform its biotechnology approval process. Branstad spoke at USDAs annual Agricultural Outlook Forum before a scheduled meeting at the Chinese embassy in Washington, We soon hope to reopen the market for American beef, Branstad said. I want to serve it at the (U.S.) embassy and I certainly want to do what I can to convince the Chinese leadership to do that sooner than later. It was in September last year that China announced it was going to lift its 14-year-old ban on U.S. beef, but there have been no signs since then that the country was actually following through with that promise. China was just one of many countries that banned U.S. beef in 2003 after theU.S. discovered its first case of bovine spongiform encephalopathy (BSE).Since then most countries have lifted those bans, and in 2013 the World Organization for Animal Health (OIE) announced that it was placing the U.S. into the negligible, or lowest risk category, for BSE, … Continue reading →

Innovation not necessarily comprises a scientific breakthrough but seeks the immediacy of needs to be acknowledged, asserts Rabindra Mohan Sapkota, 43, who is the chairman of Shikhar Biotech established in 2000. In conversation with Republicas Sonam Lama, he shares some of his insights on initiating the first biotechnological company in Nepal, followed by its different setbacks. Tell us about Shikhar Biotech? Shikhar Biotech is pioneer antibody production company in Nepal which was initiated by the parent biotech company based in the United Kingdom. Our company is a spin-off of the British-Nepali venture Everest Biotech Limited, UK. We aim to manufacture and deliver the highest quality reagents and services to life-science researchers and other biotech companies worldwide. How is Shikhar Biotech different from other biotech companies? Yes. Many experiments in Nepal are carried out on plant biotechnology but we have been conducting a specific operation on producing and manufacturing goat antibodies. With a smooth manufacture and delivery of more than 3000 antibodies till date, we believe we are attained a renowned space in the international market with our products being on long term demand. We have a strong track record of testing thousands of high quality goat polyclonal antibodies on behalf … Continue reading →

Generex Biotechnology Corporation (OTCMKTS:GNBT) is a micro-cap biotech player that has been on the rise of late despite an avalanche of growing debt and no clear route to near term monetization. But such is the case quite often in this sector, even in the case of the best opportunities. GNBT stockis moving higher in recent days following a couple catalysts. In the first case, the company announced a letter of intent for the acquisition of a controlling equity interest in Emmaus Life Sciences, Inc, a biopharmaceutical company engaged in the discovery, development, and commercialization of innovative treatments and therapies, primarily for rare and orphan disease. Initial product development efforts are focused on Sickle Cell Disease (SCD), a genetic disorder. In the second case, the company just announced that it has achieved the elimination of its outstanding derivative securities. Generex Biotechnology Corporation (OTCMKTS:GNBT) trumpets itself as a company engaged in the research, development, and commercialization of drug delivery systems and technologies. As the company states, Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Companys proprietary liquid formulations allow drugs typically administered by … Continue reading →

Market Summary Follow Puma Biotechnology Inc is a A biopharmaceutical company PBYI - Market Data & News PBYI - Stock Valuation Report Puma Biotechnology Inc (PBYI) had a rough trading day for Wednesday February 22 as shares tumbled 10.56%, or a loss of $-4.05 per share, to close at $34.30. After opening the day at $38.05, shares of Puma Biotechnology Inc traded as high as $38.50 and as low as $34.25. Volume was 890,673 shares over 7,101 trades, against an average daily volume of 936,446 shares and a total float of 36.82 million. As a result of the decline, Puma Biotechnology Inc now has a market cap of $1.26 billion. In the last year, shares of Puma Biotechnology Inc have traded between a range of $73.27 and $19.74, and its 50-day SMA is currently $34.41 and 200-day SMA is $41.71. For a complete fundamental analysis of Puma Biotechnology Inc, check out Equities.coms Stock Valuation Analysis report for PBYI. Want to invest with the experts? Subscribe to Equities Premium newsletters today! Visit http://www.equitiespremium.com/ to learn more about Guild Investments Market Commentary and Adam Sarhans Find Leading Stocks today. Puma Biotechnology Inc is a biopharmaceutical company. It is engaged in the acquisition, … Continue reading →

Patch.com Minuteman HS Receives Biotechnology Lab Grant Patch.com From Minuteman HS:Minuteman High School has landed another major grant from the Massachusetts Life Sciences Center to help upgrade its Biotechnology program. The $108,172 competitive grant will enable the school to outfit its Biotechnology lab with ... Read more from the original source: Minuteman HS Receives Biotechnology Lab Grant - Patch.com … Continue reading →

MPs on Tuesday clashed with biotechnology researchers over the lifting of the GMO ban. The law makers dismissed a call to have the ban lifted and called for development of home grown biotechnology solutions rather than imposing "foreign ideologies". Our researchers should focus on home grown technologies that address some of the challenges farmers are facing such as aflatoxin, drought tolerant crop varieties and the stem borer pest, said Agriculture Parliamentary committee chair Noor Mohammed. He assured local scientists that as long as they focus on need based research, the committee will lobby the government to allocate more resources. Mohammed made the remarks during a consultative meeting between the committee and biotechnology stakeholders. He noted that there has not been any scientific evidence on the safety of GMOs, or any guarantee that it can offer a solution to food insecurity in the country. Read: University students want government to issue licence of GMO maize Also read: State launches GMO labelling mark amid jitters of effect on existent ban There is no research in the world specifically stating on the safety of the technology. Let any scientist give evidence in Kenya own up and that GMO is safe for human consumption, … Continue reading →